CoChat
Sign Up
Cited by 1,424Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Alzheimer’s Disease: The Challenge of the Second Century

Open access
Holtzman, David M., Morris, John C., Goate, Alison M.·2011·Science Translational Medicine
DOI 10.1126/scitranslmed.3002369PMC PMC3130546
Open this paper in CoChat — free account

Abstract

In the first of our State of the Art Review series, David M. Holtzman, John C. Morris, and Alison M. Goate explore the rapid pace of Alzheimer’s disease research and the challenges to translating research breakthroughs into clinical treatments.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3002369

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • AD pathology, such as cerebral Aβ accumulation, probably begins one to two decades before onset of clinical symptoms.

    “Growing evidence suggests that AD pathology, such as cerebral Aβ accumulation, probably begins one to two decades before onset of clinical symptoms (Holtzman et al. 2011, Perrin et al. 2009).”

    From miR‐186 is decreased in aged brain and suppresses <scp>BACE</scp>1 expression (2016) · cites this paper as Holtzman et al. 2011

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 154

  1. [2]Barker WW Luis CA Kashuba A Luis M Harwood DG Loewenstein D Waters C Jimison P Shepherd E Sevush S Graff-Radford N Newland D Todd M Miller B Gold M Heilman K Doty L Goodman I Robinson B Pearl G Dickson D Duara R Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank Alzheimer Dis Assoc Disord 16 203 212 2002 12468894
  2. [3]Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules Neurology 43 2412 2414 1993 8232972
  3. [5]Klunk WE Engler H Nordberg A Wang Y Blomqvist G Holt DP Bergstrom M Savitcheva I Huang GF Estrada S Ausen B Debnath ML Barletta J Price JC Sandell J Lopresti BJ Wall A Koivisto P Antoni G Mathis CA Langstrom B Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B Ann Neurol 55 306 319 2004 14991808
  4. [6]Clark CM Schneider JA Bedell BJ Beach TG Bilker WB Mintun MA Pontecorvo MJ Hefti F Carpenter AP Flitter ML Krautkramer MJ Kung HF Coleman RE Doraiswamy PM Fleisher AS Sabbagh MN Sadowsky CH Reiman PE Zehntner SP Skovronsky DM Use of florbetapir-PET for imaging beta-amyloid pathology Jama 305 275 283 2011 21245183 PMC7041965
  5. [9]Price JL Ko AI Wade MJ Tsou SK McKeel DW Morris JC Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer Disease Arch Neurol 58 1395 1402 2001 11559310
  6. [10]Price JL Morris JC Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease Ann Neurol 45 358 368 1999 10072051
  7. [12]Jack CR Jr Knopman DS Jagust WJ Shaw LM Aisen PS Weiner MW Petersen RC Trojanowski JQ Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade Lancet Neurol 9 119 128 2010 20083042 PMC2819840
  8. [14]Golde TE Eckman CB Younkin SG Biochemical detection of Ab isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease Biochim Biophys Acta 1502 172 187 2000 10899442
  9. [17]Koffie RM Meyer-Luehmann M Hashimoto T Adams KW Mielke ML Garcia-Alloza M Micheva KD Smith SJ Kim ML Lee VM Hyman BT Spires-Jones TL Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques Proc Natl Acad Sci U S A 106 4012 4017 2009 19228947 PMC2656196
  10. [18]Lucin KM Wyss-Coray T Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 64 110 122 2009 19840553 PMC2834890
  11. [20]Smith EE Greenberg SM Beta-amyloid, blood vessels, and brain function Stroke 40 2601 2606 2009 19443808 PMC2704252
  12. [21]Greenberg SM Frosch MP Life imitates art: Anti-amyloid antibodies and inflammatory cerebral amyloid angiopathy Neurology 76 772 773 2011 21357829
  13. [22]Soontornniyomkij V Lynch MD Mermash S Pomakian J Badkoobehi H Clare R Vinters HV Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy Brain Pathol 20 459 467 2010 19725828 PMC3127860
  14. [23]Braak H Braak E Frequency of stages of Alzheimer-related lesions in different age categories Neurobiol Aging 18 351 357 1997 9330961
  15. [24]Goedert M Wischik CM Crowther RA Walker JE Klug A Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau Proc Natl Acad Sci U S A 85 4051 4055 1988 3131773 PMC280359
  16. [25]Wischik CM Novak M Edwards PC Klug A Tichelaar W Crowther RA Structural characterization of the core of the paired helical filament of Alzheimer disease Proc Natl Acad Sci U S A 85 4884 4888 1988 2455299 PMC280541
  17. [26]Wischik CM Novak M Thogersen HC Edwards PC Runswick MJ Jakes R Walker JE Milstein C Roth M Klug A Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease Proc Natl Acad Sci U S A 85 4506 4510 1988 3132715 PMC280459
  18. [27]Grundke-Iqbal I Iqbal K Tung YC Quinlan M Wisniewski HM Binder LI Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology Proc Natl Acad Sci U S A 83 4913 4917 1986 3088567 PMC323854
  19. [28]Kidd M Paired helical filaments in electron microscopy of Alzheimer’s disease Nature 197 192 193 1963 14032480
  20. [30]Small SA Duff K Linking Abeta and tau in late-onset Alzheimer’s disease: a dual pathway hypothesis Neuron 60 534 542 2008 19038212 PMC2692134
  21. [31]Coyle JT Price DL DeLong MR Alzheimer’s disease: a disorder of cortical cholinergic innervation Science 219 1184 1190 1983 6338589
  22. [32]Davies P Maloney AJ Selective loss of central cholinergic neurons in Alzheimer’s disease Lancet 2 1403 1976 63862
  23. [33]Farlow MR Miller ML Pejovic V Treatment options in Alzheimer’s disease: maximizing benefit, managing expectations Dement Geriatr Cogn Disord 25 408 422 2008 18391487
  24. [34]Areosa SA Sherriff F McShane R Memantine for dementia Cochrane Database Syst Rev CD003154 2005 15846650
  25. [36]Greicius MD Srivastava G Reiss AL Menon V Default-mode network activity distinguishes Alzheimer’s disease from healthy aging: evidence from functional MRI Proc Natl Acad Sci U S A 101 4637 4642 2004 15070770 PMC384799
  26. [37]Sperling RA Laviolette PS O’Keefe K O’Brien J Rentz DM Pihlajamaki M Marshall G Hyman BT Selkoe DJ Hedden T Buckner RL Becker JA Johnson KA Amyloid deposition is associated with impaired default network function in older persons without dementia Neuron 63 178 188 2009 19640477 PMC2738994
  27. [39]Raichle ME MacLeod AM Snyder AZ Powers WJ Gusnard DA Shulman GL A default mode of brain function Proc Natl Acad Sci U S A 98 676 682 2001 11209064 PMC14647
  28. [40]Cirrito JR Yamada KA Finn MB Sloviter RS Bales KR May PC Schoepp DD Paul SM Mennerick S Holtzman DM Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo Neuron 48 913 922 2005 16364896
  29. [41]Kamenetz F Tomita T Hsieh H Seabrook G Borchelt D Iwatsubo T Sisodia S Malinow R APP processing and synaptic function Neuron 37 925 937 2003 12670422
  30. [43]Frost B Diamond MI Prion-like mechanisms in neurodegenerative diseases Nat Rev Neurosci 11 155 159 2010 20029438 PMC3648341
  31. [45]Eisele YS Obermuller U Heilbronner G Baumann F Kaeser SA Wolburg H Walker LC Staufenbiel M Heikenwalder M Jucker M Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis Science 330 980 982 2010 20966215 PMC3233904
  32. [47]Glenner GG Wong CW Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein Biochem Biophys Res Commun 120 885 890 1984 6375662
  33. [48]Masters CL Simms G Weinman NA Multhaup G McDonald BL Beyreuther K Amyloid plaque core protein in Alzheimer disease and Down syndrome Proc Natl Acad Sci U S A 82 4245 4249 1985 3159021 PMC397973
  34. [49]Lai F Williams RS A prospective study of Alzheimer disease in Down syndrome Arch Neurol 46 849 853 1989 2527024
  35. [50]Wisniewski KE Wisniewski HM Wen GY Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome Ann Neurol 17 278 282 1985 3158266
  36. [51]Goldgaber D Lerman MI McBride OW Saffiotti U Gajdusek DC Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer’s disease Science 235 877 880 1987 3810169
  37. [54]Van Nostrand WE Wagner SL Suzuki M Choi BH Farrow JS Geddes JW Cotman CW Cunningham DD Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor Nature 341 546 549 1989 2507928
  38. [55]Smith RP Higuchi DA Broze GJ Jr Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein Science 248 1126 1128 1990 2111585
  39. [56]Golde TE Estus S Younkin LH Selkoe DJ Younkin SG Processing of the amyloid protein precursor to potentially amyloidogenic derivatives Science 255 728 730 1992 1738847
  40. [60]Goate A Chartier-Harlon MC Mullan M Brown J Crawford F Fidani L Giuffra L Haynes A Irving N James L Mant R Newton P Roote K Roques P Talbot C Pericak-Vance M Roses A Williamson R Rossor M Owen M Hardy J Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease Nature 349 704 706 1991 1671712
  41. [61]Levy E Carman MD Fernandez MIJ Power MD Lieberburg I van Duinen SG Bots GT Luyendijk W Frangione B Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type Science 248 1124 1126 1990 2111584
  42. [62]Van Broeckhoven C Haan J Bakker E Hardy JA Van Hul W Wehnert A Vegter-Van der Vlis M Roos RA Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch) Science 248 1120 1122 1990 1971458
  43. [63]Chartier-Harlin MC Crawford F Houlden H Warren A Hughes D Fidani L Goate A Rossor M Roques P Hardy J Early-onset Alzheimer’s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene Nature 353 844 846 1991 1944558
  44. [64]Murrell J Farlow M Ghetti B Benson M A mutation in the amyloid precursor protein associated with hereditary Alzheimer’s disease Science 254 97 99 1991 1925564
  45. [65]Davis J Van Nostrand WE Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein Proc Natl Acad Sci USA 93 2996 3000 1996 8610157 PMC39749
  46. [66]Grabowski TJ Cho HS Vonsattel JPG Rebeck GW Greenberg SM Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy Ann Neurol 49 697 705 2001 11409420
  47. [67]Van Nostrand WE Melchor JP Soon Cho H Greenberg SM Rebeck GW Pathogenic effects of D23N Iowa mutant amyloid-protein J Biol Chem 276 32860 32866 2001 11441013
  48. [68]Haass C Hung AY Selkoe DJ Teplow DB Mutations associated with a locus for familial Alzheimer’s J Biol Chem 269 17741 17748 1994 8021287
  49. [69]Suzuki N Cheung TT Cai XD Odaka A Otvos LJ Eckman C Golde TE Younkin SG An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants Science 264 1336 1340 1994 8191290
  50. [70]Jarrett JT Berger EP Lansbury PT The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease Biochemistry 32 4693 4697 1993 8490014
  51. [73]Cai X-D Golde TE Younkin SG Release of excess amyloid protein from a mutant amyloid β protein precursor Science 259 514 516 1993 8424174
  52. [75]Rovelet-Lecrux A Hannequin D Raux G Le Meur N Laquerriere A Vital A Dumanchin C Feuillette S Brice A Vercelletto M Dubas F Frebourg T Campion D APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy Nat Genet 38 24 26 2006 16369530
  53. [76]Nilsberth C Westlind-Danielsson A Eckman CB Condron MM Axelman K Forsell C Stenh C Luthman J Teplow DB Younkin SG Naslund J Lannfelt L The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation Nature Neurosci 4 887 893 2001 11528419
  54. [77]Tomiyama T Nagata T Shimada H Teraoka R Fukushima A Kanemitsu H Takuma H Kuwano R Imagawa M Ataka S Wada Y Yoshioka E Nishizaki T Watanabe Y Mori H A new amyloid beta variant favoring oligomerization in Alzheimer’s-type dementia Ann Neurol 63 377 387 2008 18300294
  55. [78]Cloe AL Orgel JP Sachleben JR Tycko R Meredith SC The Japanese Mutant Abeta (DeltaE22-Abeta(1-39)) Forms Fibrils Instantaneously, with Low-Thioflavin T Fluorescence: Seeding of Wild-Type Abeta(1-40) into Atypical Fibrils by DeltaE22-Abeta(1-39) Biochemistry 2011 PMC3631511 21291268
  56. [79]Wang P Yang G Mosier DR Chang P Zaidi T Gong YD Zhao NM Dominguez B Lee KF Gan WB Zheng H Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2 J Neurosci 25 1219 1225 2005 15689559 PMC6725967
  57. [80]Nikolaev A McLaughlin T O’Leary DD Tessier-Lavigne M APP binds DR6 to trigger axon pruning and neuron death via distinct caspases Nature 457 981 989 2009 19225519 PMC2677572
  58. [81]Young-Pearse TL Suth S Luth ES Sawa A Selkoe DJ Biochemical and functional interaction of disrupted-in-schizophrenia 1 and amyloid precursor protein regulates neuronal migration during mammalian cortical development J Neurosci 30 10431 10440 2010 20685985 PMC3018837
  59. [82]Ring S Weyer SW Kilian SB Waldron E Pietrzik CU Filippov MA Herms J Buchholz C Eckman CB Korte M Wolfer DP Muller UC The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice J Neurosci 27 7817 7826 2007 17634375 PMC6672885
  60. [83]Wei W Nguyen LN Kessels HW Hagiwara H Sisodia S Malinow R Amyloid beta from axons and dendrites reduces local spine number and plasticity Nat Neurosci 13 190 196 2010 20037574 PMC3310198
  61. [85]Sherrington R Rogaev EI Liang Y Rogaeva EA Levesque G Ikeda M Chi H Lin C Li G Holman K Tsuda T Mar L Foncin J-F Bruni AC Montesi MP Sorbi S Rainero I Pinessi L Nee L Chumakov I Pollen D Brookes A Sanseau P Polinsky RJ Wasco W Da Silva HAR Haines JL Pericak-Vance MA Tanzi RE Roses AD Fraser PE Rommens JM St George-Hyslop PH Cloning a a gene bearing missense mutations in early-onset familial Alzheimer’s disease Nature 375 754 760 1995 7596406
  62. [88]Takasugi N Tomita T Hayashi I Tsuruoka M Niimura M Takahashi Y Thinakaran G Iwatsubo T The role of presenilin cofactors in the gamma-secretase complex Nature 422 438 441 2003 12660785
  63. [89]Edbauer D Winkler E Regula JT Pesold B Steiner H Haass C Reconstitution of gamma-secretase activity Nat Cell Biol 5 486 488 2003 12679784
  64. [90]Thinakaran G The role of presenilins in Alzheimer’s disease J Clin Invest 104 1321 1327 1999 10562290 PMC409849
  65. [91]Li Y-M Xu M Lai M-T Huang Q Castro JL Dimuzio-Mower J Harrrison T Lellis C Nadin A NJG Register RB Sardana MK SMS Smith AL Shi X-P Yin K-C Shafer JA Gardell SJ Photoactivated -secretase inhibitors directed to the active site covalently label presenilin 1 Nature 405 689 694 2000 10864326
  66. [92]Wolfe MS Xia W Ostaszewski BL Diehl TS Kimberly WT Selkoe DJ Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity Nature 398 513 517 1999 10206644
  67. [93]Liu Z Turkoz A Jackson EN Corbo JC Engelbach JA Garbow JR Piwnica-Worms DR Kopan R Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice J Clin Invest 121 800 808 2011 21266774 PMC3026721
  68. [94]Schor NF What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us Ann Neurol 69 237 239 2011 21387368
  69. [96]Borchelt DR Ratovitski T Van Lare J Lee MK Gonzales VB Jenkins NA Copeland NG Price DL Sisodia SS Accelerated amyloid deposition in the brains of transgenic mice co-expressing mutant presenilin 1 and amyloid precursor proteins Neuron 19 939 945 1997 9354339
  70. [97]Holcomb L Gordon MN McGowan E Yu X Benkovic S Jantzen P Wright K Saad I Mueller R Morgan D Sanders S Zehr C O’Campo K Hardy J Prada C-M Eckman C Younkin S Hsaio K Duff K Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes Nature Med 4 97 100 1998 9427614
  71. [98]De Strooper B Saftig P Craessaerts K Vanderstichele H Guhde G Annaert W Von Figura K Van Leuven F Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein Nature 391 387 390 1998 9450754
  72. [99]De Strooper B Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease EMBO Rep 8 141 146 2007 17268505 PMC1796779
  73. [100]Shen J Bronson RT Chen DF Xia W Selkoe DJ Tonegawa S Skeletal and CNS defects in presenilin-1-deficient mice Cell 89 629 639 1997 9160754
  74. [101]Wong PC Zheng H Chen H Becher MW Sirinathsinghji DJS Trumbauer ME Chen HY Price DL Van der Ploeg LHT Sisodia SS Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm Nature 387 288 292 1997 9153393
  75. [102]Davis JA Naruse S Chen H Eckman C Younkin S Price DL Borchelt DR Sisodia SS Wong PC An Alzheimer’s disease-linked PS1 variant rescues the developmental abnormalities of PS1-deficient embryos Neuron 20 603 609 1998 9539132
  76. [103]Qian S Jiang P Guan X-M Singh G Trumbauer ME Yu H Chen HY Van der Ploeg LHT Zheng H Mutant human presenilin 1 protectspresenilin 1 null mouse against embryonic lethality and elevates Aβ1-42/43 expression Neuron 20 611 617 1997 9539133
  77. [104]Wang B Yang W Wen W Sun J Su B Liu B Ma D Lv D Wen Y Qu T Chen M Sun M Shen Y Zhang X Gamma-secretase gene mutations in familial acne inversa Science 330 1065 2010 20929727
  78. [105]Bateman RJ Aisen PS De Strooper B Fox NC Lemere CA Ringman JM Salloway S Sperling RA Windisch M Xiong C Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease Alzheimers Res Ther 3 1 2011 21211070 PMC3109410
  79. [106]McGowan E Pickford F Kim J Onstead L Eriksen J Yu C Skipper L Murphy MP Beard J Das P Jansen K Delucia M Lin WL Dolios G Wang R Eckman CB Dickson DW Hutton M Hardy J Golde T Abeta42 is essential for parenchymal and vascular amyloid deposition in mice Neuron 47 191 199 2005 16039562 PMC1373682
  80. [107]Kim J Onstead L Randle S Price R Smithson L Zwizinski C Dickson DW Golde T McGowan E Abeta40 inhibits amyloid deposition in vivo J Neurosci 27 627 633 2007 17234594 PMC6672801
  81. [108]Kounnas MZ Danks AM Cheng S Tyree C Ackerman E Zhang X Ahn K Nguyen P Comer D Mao L Yu C Pleynet D Digregorio PJ Velicelebi G Stauderman KA Comer WT Mobley WC Li YM Sisodia SS Tanzi RE Wagner SL Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer’s disease Neuron 67 769 780 2010 20826309 PMC2947312
  82. [109]Serneels L Van Biervliet J Craessaerts K Dejaegere T Horre K Van Houtvin T Esselmann H Paul S Schafer MK Berezovska O Hyman BT Sprangers B Sciot R Moons L Jucker M Yang Z May PC Karran E Wiltfang J D’Hooge R De Strooper B gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer’s disease Science 324 639 642 2009 19299585 PMC2740474
  83. [110]Yu G Nishimura M Arawaka S Levitan D Zhang L Tandon A Song YQ Rogaeva E Chen F Kawarai T Supala A Levesque L Yu H Yang DS Holmes E Milman P Liang Y Zhang DM Xu DH Sato C Rogaev E Smith M Janus C Zhang Y Aebersold R Farrer LS Sorbi S Bruni A Fraser P St George-Hyslop P Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing Nature 407 48 54 2000 10993067
  84. [112]Cai H Wang Y McCarthy D Wen H Borchelt DR Price DL Wong PC BACE1 is the major b-secretase for generation of Ab peptides by neurons Nature Neurosci 4 233 234 2001 11224536
  85. [114]Corder EH Saunders AM Strittmatter WJ Schmechel DE Gaskell PC Small GW Roses AD Haines JL Pericak-Vance MA Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families Science 261 921 923 1993 8346443
  86. [117]Schmechel DE Saunders AM Strittmattter WJ Crain BJ Hulette CM Joo SH Pericak-Vance MA Goldgaber D Roses AD Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein genotype in late-onset Alzheimer disease Proc Natl Acad Sci USA 90 9649 9653 1993 8415756 PMC47627
  87. [118]Greenberg SM Rebeck GW Vonsattel JPG Gomez-Isla T Hyman BT Apolipoprotein E e4 and cerebral hemorrhage associated with amyloid angiopathy Ann Neurol 38 254 259 1995 7654074
  88. [120]Biffi A Sonni A Anderson CD Kissela B Jagiella JM Schmidt H Jimenez-Conde J Hansen BM Fernandez-Cadenas I Cortellini L Ayres A Schwab K Juchniewicz K Urbanik A Rost NS Viswanathan A Seifert-Held T Stoegerer EM Tomas M Rabionet R Estivill X Brown DL Silliman SL Selim M Worrall BB Meschia JF Montaner J Lindgren A Roquer J Schmidt R Greenberg SM Slowik A Broderick JP Woo D Rosand J Variants at APOE influence risk of deep and lobar intracerebral hemorrhage Ann Neurol 68 934 943 2010 21061402 PMC3058266
  89. [122]Mahley RW Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology Science 240 622 630 1988 3283935
  90. [123]Plump AS Breslow JL Apolipoprotein E and the apolipoprotein E-deficient mouse Annu Rev Nutr 15 495 518 1995 8527231
  91. [124]Rebeck GW Reiter JS Strickland DK Hyman BT Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions Neuron 11 575 580 1993 8398148
  92. [128]Fryer JD Simmons K Parsadanian M Bales KR Paul SM Sullivan PM Holtzman DM ApoE4 alters the amyloid- 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an APP transgenic model submitted 25 2803 2810 2005 PMC6725147 15772340
  93. [129]Holtzman DM Bales KR Tenkova T Fagan AM Parsadanian M Sartorius LJ Mackey B Olney J McKeel D Wozniak D Paul SM Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease Proc Natl Acad Sci USA 97 2892 2897 2000 10694577 PMC16026
  94. [131]Kauwe JS Cruchaga C Bertelsen S Mayo K Latu W Nowotny P Hinrichs AL Fagan AM Holtzman DM Goate AM Validating predicted biological effects of Alzheimer’s disease associated SNPs using CSF biomarker levels J Alzheimers Dis 21 833 842 2010 20634593 PMC3032214
  95. [132]Choi-Miura NH Ihara Y Fukuchi K Takeda M Nakano Y Tobe T Tomita M SP-40,40 is a constituent of Alzheimer’s amyloid Acta Neuropath 83 260 264 1992 1373021
  96. [133]DeMattos RB O’dell MA Parsadanian M Taylor JW Harmony JAK Bales KR Paul SM Aronow BJ Holtzman DM Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer’s disease Proc Natl Acad Sci USA 10 10843 10848 2002 12145324 PMC125060
  97. [134]Qiu WQ Borth W Ye Z Haass C Teplow DB Selkoe DJ Degradation of amyloid beta-protein by a serine protease-alpha2 -macroglobulin complex J Biol Chem 271 8443 8451 1996 8626544
  98. [135]Goldgaber D Schwarzman AI Bhasin R Gregori L Schmechel D Saunders AM Roses AD Strittmatter WJ Sequestration of amyloid beta-peptide Ann NY Acad Sci 695 139 143 1993 8239272
  99. [136]Mucke L Yu GQ McConlogue L Rockenstein EM Abraham CR Masliah E Astroglial expression of human alpha(1)-antichymotrypsin enhances Alzheimer-like pathology in amyloid protein precursor transgenic mice Am J Pathol 157 2003 2010 2000 11106573 PMC1885780
  100. [138]Bertram L Lill CM Tanzi RE The genetics of Alzheimer disease: back to the future Neuron 68 270 281 2010 20955934
  101. [139]Wray NR Goddard ME Visscher PM Prediction of individual genetic risk of complex disease Curr Opin Genet Dev 18 257 263 2008 18682292
  102. [140]Cirulli ET Goldstein DB Uncovering the roles of rare variants in common disease through whole-genome sequencing Nat Rev Genet 11 415 425 2010 20479773
  103. [141]Bertram L Lange C Mullin K Parkinson M Hsiao M Hogan MF Schjeide BM Hooli B Divito J Ionita I Jiang H Laird N Moscarillo T Ohlsen KL Elliott K Wang X Hu-Lince D Ryder M Murphy A Wagner SL Blacker D Becker KD Tanzi RE Genome-wide association analysis reveals putative Alzheimer’s disease susceptibility loci in addition to APOE Am J Hum Genet 83 623 632 2008 18976728 PMC2668052
  104. [143]Lambert JC Heath S Even G Campion D Sleegers K Hiltunen M Combarros O Zelenika D Bullido MJ Tavernier B Letenneur L Bettens K Berr C Pasquier F Fievet N Barberger-Gateau P Engelborghs S De Deyn P Mateo I Franck A Helisalmi S Porcellini E Hanon O de Pancorbo MM Lendon C Dufouil C Jaillard C Leveillard T Alvarez V Bosco P Mancuso M Panza F Nacmias B Bossu P Piccardi P Annoni G Seripa D Galimberti D Hannequin D Licastro F Soininen H Ritchie K Blanche H Dartigues JF Tzourio C Gut I Van Broeckhoven C Alperovitch A Lathrop M Amouyel P Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease Nat Genet 41 1094 1099 2009 19734903
  105. [144]Seshadri S Fitzpatrick AL Ikram MA DeStefano AL Gudnason V Boada M Bis JC Smith AV Carassquillo MM Lambert JC Harold D Schrijvers EM Ramirez-Lorca R Debette S Longstreth WT Jr Janssens AC Pankratz VS Dartigues JF Hollingworth P Aspelund T Hernandez I Beiser A Kuller LH Koudstaal PJ Dickson DW Tzourio C Abraham R Antunez C Du Y Rotter JI Aulchenko YS Harris TB Petersen RC Berr C Owen MJ Lopez-Arrieta J Varadarajan BN Becker JT Rivadeneira F Nalls MA Graff-Radford NR Campion D Auerbach S Rice K Hofman A Jonsson PV Schmidt H Lathrop M Mosley TH Au R Psaty BM Uitterlinden AG Farrer LA Lumley T Ruiz A Williams J Amouyel P Younkin SG Wolf PA Launer LJ Lopez OL van Duijn CM Breteler MM Genome-wide analysis of genetic loci associated with Alzheimer disease Jama 303 1832 1840 2010 20460622 PMC2989531
  106. [146]Hollingworth Nature Genet in press 2011
  107. [148]Choi M Scholl UI Ji W Liu T Tikhonova IR Zumbo P Nayir A Bakkaloglu A Ozen S Sanjad S Nelson-Williams C Farhi A Mane S Lifton RP Genetic diagnosis by whole exome capture and massively parallel DNA sequencing Proc Natl Acad Sci U S A 106 19096 19101 2009 19861545 PMC2768590
  108. [149]Hinrichs AL Mintun MA Head D Fagan AM Holtzman DM Morris JC Goate AM Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer’s disease Biol Psychiatry 67 581 583 2010 19892322 PMC2866645
  109. [150]Lambert JC Sleegers K Gonzalez-Perez A Ingelsson M Beecham GW Hiltunen M Combarros O Bullido MJ Brouwers N Bettens K Berr C Pasquier F Richard F Dekosky ST Hannequin D Haines JL Tognoni G Fievet N Dartigues JF Tzourio C Engelborghs S Arosio B Coto E De Deyn P Del Zompo M Mateo I Boada M Antunez C Lopez-Arrieta J Epelbaum J Schjeide BM Frank-Garcia A Giedraitis V Helisalmi S Porcellini E Pilotto A Forti P Ferri R Delepine M Zelenika D Lathrop M Scarpini E Siciliano G Solfrizzi V Sorbi S Spalletta G Ravaglia G Valdivieso F Vepsalainen S Alvarez V Bosco P Mancuso M Panza F Nacmias B Bossu P Hanon O Piccardi P Annoni G Mann D Marambaud P Seripa D Galimberti D Tanzi RE Bertram L Lendon C Lannfelt L Licastro F Campion D Pericak-Vance MA Soininen H Van Broeckhoven C Alperovitch A Ruiz A Kamboh MI Amouyel P The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer’s disease: a meta-analysis study J Alzheimers Dis 22 247 255 2010 20847397 PMC2964875
  110. [151]Cruchaga C Kauwe JS Mayo K Spiegel N Bertelsen S Nowotny P Shah AR Abraham R Hollingworth P Harold D Owen MM Williams J Lovestone S Peskind ER Li G Leverenz JB Galasko D Morris JC Fagan AM Holtzman DM Goate AM SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer’s disease PLoS Genet 6 2010 PMC2940763 20862329
  111. [152]O’Meara ES Kukull WA Sheppard L Bowen JD McCormick WC Teri L Pfanschmidt M Thompson JD Schellenberg GD Larson EB Head injury and risk of Alzheimer’s disease by apolipoprotein E genotype Am J Epidemiol 146 373 384 1997 9290497
  112. [153]Tang MX Maestre G Tsai WY Liu XH Feng L Chung WY Chun M Schofield P Stern Y Tycko B Mayeux R Effect of age, ethnicity, and head injury on the association between APOE genotypes and Alzheimer’s disease Ann N Y Acad Sci 802 6 15 1996 8993479
  113. [154]Jordan BD Relkin NR Ravdin LD Jacobs AR Bennett A Gandy S Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing Jama 278 136 140 1997 9214529
  114. [157]Roe CM Mintun MA D’Angelo G Xiong C Grant EA Morris JC Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake Arch Neurol 65 1467 1471 2008 19001165 PMC2752218
  115. [158]Lazarov O Robinson J Tang YP Hairston IS Korade-Mirnics Z Lee VM Hersh LB Sapolsky RM Mirnics K Sisodia SS Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice Cell 120 701 713 2005 15766532
  116. [162]Hsiao K Chapman P Nilsen S Eckman C Harigaya Y Youkin S Yang F Cole G Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice Science 274 99 102 1996 8810256
  117. [163]Irizarry MC Soriano F McNamara M Page KJ Schenk D Games D Hyman BT Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse submitted 17 7053 7059 1997 PMC6573263 9278541
  118. [164]Masliah E Sisk A Mallory M Mucke L Schenk D Games D Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer’s disease submitted 16 5795 5811 1996 PMC6578961 8795633
  119. [167]Araki T Sasaki Y Milbrandt J Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration Science 305 1010 1013 2004 15310905
  120. [169]Hutton M Molecular genetics of chromosome 17 tauopathies Ann NY Acad Sci 920 63 73 2000 11193178
  121. [171]Poorkaj P Bird TD Wijsman E Nemens E Garruto RM Anderson L Andreadis A Wiederholt WC Raskind M Schellenberg GD Tau is a candidate gene for chromosome 17 frontotemporal dementia Ann Neurol 43 815 825 1998 9629852
  122. [172]Lewis J McGowan E Rockwood J Melrose H Nacharaju P Van Slegtenhorst M Gwinn-Hardy K PaulMurphy M Baker M Yu X Duff K Hardy J Corral A Lin WL Yen SH Dickson DW Davies P Hutton M Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein Nature Genet; 25 402 405 2001 10932182
  123. [173]Santacruz K Lewis J Spires T Paulson J Kotilinek L Ingelsson M Guimaraes A DeTure M Ramsden M McGowan E Forster C Yue M Orne J Janus C Mariash A Kuskowski M Hyman B Hutton M Ashe KH Tau suppression in a neurodegenerative mouse model improves memory function Science 309 476 481 2005 16020737 PMC1574647
  124. [174]Kauwe JS Cruchaga C Mayo K Fenoglio C Bertelsen S Nowotny P Galimberti D Scarpini E Morris JC Fagan AM Holtzman DM Goate AM Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition Proc Natl Acad Sci U S A 105 8050 8054 2008 18541914 PMC2430357
  125. [175]Gotz J Chen F van Dorpe J Nitsch RM Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils Science 293 1491 1495 2001 11520988
  126. [176]Lewis J Dickson DW Lin WL Chisholm L Corral A Jones G Yen SH Sahara N Skipper L Yager D Eckman C Hardy J Hutton M McGowan E Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP Science 293 1487 1491 2001 11520987
  127. [177]Oddo S Billings L Kesslak JP Cribbs DH LaFerla FM Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome Neuron 43 321 332 2004 15294141
  128. [178]Caughey B Lansbury PT Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders Annu Rev Neurosci 26 267 298 2003 12704221
  129. [179]Glabe CG Common mechanisms of amyloid oligomer pathogenesis in degenerative disease Neurobiol Aging 27 570 575 2006 16481071
  130. [181]Shankar GM Li S Mehta TH Garcia-Munoz A Shepardson NE Smith I Brett FM Farrell MA Rowan MJ Lemere CA Regan CM Walsh DM Sabatini BL Selkoe DJ Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 14 837 842 2008 18568035 PMC2772133
  131. [184]Zlokovic BV Neurovascular mechanisms of Alzheimer’s neurodegeneration Trends Neurosci 28 202 208 2005 15808355
  132. [185]Chin J Palop JJ Yu GQ Kojima N Masliah E Mucke L Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice J Neurosci 24 4692 4697 2004 15140940 PMC6729387
  133. [186]Roberson ED Scearce-Levie K Palop JJ Yan F Cheng IH Wu T Gerstein H Yu GQ Mucke L Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model Science 316 750 754 2007 17478722
  134. [187]Cisse M Halabisky B Harris J Devidze N Dubal DB Sun B Orr A Lotz G Kim DH Hamto P Ho K Yu GQ Mucke L Reversing EphB2 depletion rescues cognitive functions in Alzheimer model Nature 469 47 52 2011 21113149 PMC3030448
  135. [194]Janus C Pearson J McLaurin J Mathews PM Jiang Y Schmidt SD Chishti MA Horne P Heslin D French J Mount HTJ Nixon RA Mercken M Bergeron C Fraser PE St George-Hyslop P Westaway D Ab peptide immunization reduced behavioural impairment and plaques in a model of Alzheimer’ s disease Nature 408 979 982 2000 11140685
  136. [195]Morgan D Diamond DM Gottschall PE Ugen KE Dickey C Hardy J Duff K Jantzen P Dicarlo G Wilcock D Connor K Hatcher J Hope C Gordon M Arendash GW Ab peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease Nature 408 982 985 2000 11140686
  137. [196]Weiner HL Lemere CA Maron R Spooner ET Grenfell TJ Mori C Issazadeh S Hancock WW Selkoe DJ Nasal administration of amyloid-b peptide decreases cerebral amyloid burden in a mouse model of Alzheimer’s disease Ann Neurol 48 567 579 2000 11026440
  138. [197]Brendza RP Bacskai BJ Cirrito JR Simmons KA Skoch JM Klunk WE Mathis CA Bales KR Paul SM Hyman BT Holtzman DM Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice J Clin Invest 2005 PMC544607 15668737
  139. [199]Holtzman DM Alzheimer’s disease: Moving towards a vaccine Nature 454 418 420 2008 18650906
  140. [200]Sydow A Van der Jeugd A Zheng F Ahmed T Balschun D Petrova O Drexler D Zhou L Rune G Mandelkow E D’Hooge R Alzheimer C Mandelkow EM Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic tau mutant J Neurosci 31 2511 2525 2011 21325519 PMC6623704
  141. [201]Terwel D Muyllaert D Dewachter I Borghgraef P Croes S Devijver H Van Leuven F Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice Am J Pathol 172 786 798 2008 18258852 PMC2258274
  142. [202]Fagan AM Mintun MA Mach RH Lee SY Dence CS Shah AR LaRossa GN Spinner ML Klunk WE Mathis CA DeKosky ST Morris JC Holtzman DM Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans Ann Neurol 59 512 519 2006 16372280
  143. [203]Fagan AM Mintun MA Shah AR Aldea P Roe CM Mach RH Marcus D Morris JC Holtzman DM Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease EMBO Mol Med 1 371 380 2009 20049742 PMC2806678
  144. [204]Jagust WJ Landau SM Shaw LM Trojanowski JQ Koeppe RA Reiman EM Foster NL Petersen RC Weiner MW Price JC Mathis CA Relationships between biomarkers in aging and dementia Neurology 73 1193 1199 2009 19822868 PMC2764726
  145. [205]Craig-Schapiro R Perrin RJ Roe CM Xiong C Carter D Cairns NJ Mintun MA Peskind ER Li G Galasko DR Clark CM Quinn JF D’Angelo G Malone JP Townsend RR Morris JC Fagan AM Holtzman DM YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer’s Disease Biol Psychiatry in press 2010 PMC3011944 21035623
  146. [206]Fagan AM Roe CM Xiong C Mintun MA Morris JC Holtzman DM Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults Arch Neurol 64 343 349 2007 17210801
  147. [207]Jack CR Jr Wiste HJ Vemuri P Weigand SD Senjem ML Zeng G Bernstein MA Gunter JL Pankratz VS Aisen PS Weiner MW Petersen RC Shaw LM Trojanowski JQ Knopman DS Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease Brain 133 3336 3348 2010 20935035 PMC2965425
  148. [208]Li G Sokal I Quinn JF Leverenz JB Brodey M Schellenberg GD Kaye JA Raskind MA Zhang J Peskind ER Montine TJ CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study Neurology 69 631 639 2007 17698783
  149. [210]Hansson O Zetterberg H Buchhave P Londos E Blennow K Minthon L Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 228 234 2006 16488378
  150. [212]Aisen PS Andrieu S Sampaio C Carrillo M Khachaturian ZS Dubois B Feldman HH Petersen RC Siemers E Doody RS Hendrix SB Grundman M Schneider LS Schindler RJ Salmon E Potter WZ Thomas RG Salmon D Donohue M Bednar MM Touchon J Vellas B Report of the task force on designing clinical trials in early (predementia) AD Neurology 76 280 286 2011 21178097 PMC3034393
  151. [213]Aisen PS Alzheimer’s disease therapeutic research: the path forward Alzheimers Res Ther 1 2 2009 19674435 PMC2719107
  152. [214]Bateman RJ Munsell LY Morris JC Swarm R Yarasheski KE Holtzman DM Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo Nat Med 12 856 861 2006 16799555 PMC2983090
  153. [216]Mawuenyega KG Sigurdson W Ovod V Munsell L Kasten T Morris JC Yarasheski KE Bateman RJ Decreased clearance of CNS beta-amyloid in Alzheimer’s disease Science 330 1774 2010 21148344 PMC3073454
  154. [217]Kang JE Lim MM Bateman RJ Lee JJ Smyth LP Cirrito JR Fujiki N Nishino S Holtzman DM Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle Science 326 1005 1007 2009 19779148 PMC2789838

Cited by

Sorted by citations

Authors
Holtzman, D. M., Morris, J. C., & Goate, A. M.
Affiliations
Washington University in St. Louis (US)
ORCID
Venue
Science Translational Medicine
Publisher
American Association for the Advancement of Science (AAAS)
Published
2011-04-06
Volume
3
Issue
77
Pages
77sr1-77sr1
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
DOI
10.1126/scitranslmed.3002369
PMC
PMC3130546
OpenAlex
W2005483591
Cited by
1,424
References
64
Citations by year
2026: 53 · 2025: 81 · 2024: 99 · 2023: 102 · 2022: 93 · 2021: 93 · 2020: 100 · 2019: 124 · 2018: 116 · 2017: 101 · 2016: 92 · 2015: 95 · 2014: 95 · 2013: 86 · 2012: 69
FWCI
9.56
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Aging (R01AG035083, RC1AG035654, P50AG005681, P01AG003991, R37AG013956, U19AG032438, U01AG032438, R01AG016208, P01AG026276)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, dementia, disease prevalence, pathogenesis, translational research, early detection
MeSH terms
Alzheimer Disease, Humans, Amyloid beta-Peptides, tau Proteins, Disease Progression, Presenilins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review